Recent Broad Publications
- Small-Molecule Inhibitors of Cytokine-Mediated STAT1 Signal Transduction in β-Cells with Improved Aqueous Solubility.
Read More / View Supplemental Materials - Transcriptional and Epigenetic Dynamics during Specification of Human Embryonic Stem Cells.
Read More / View Supplemental Materials - Entering the age of whole-exome sequencing in rheumatic diseases: Novel insights into disease pathogenicity.
Read More / View Supplemental Materials - Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive.
Read More / View Supplemental Materials - miR-155 in Acute Myeloid Leukemia: Not Merely a Prognostic Marker?
Read More / View Supplemental Materials
Scientific Publications
< Back to Publications
Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.
| Publication Type | Journal Article |
| Authors | Nieland, TJ, Shaw JT, Jaipuri FA, Maliga Z., Duffner JL, Koehler AN, and Krieger M. |
| Abstract | Treatment of atherosclerotic disease often focuses on reducing plasma LDL-cholesterol or increasing plasma HDL-cholesterol. We examined in vitro the effects on HDL receptor [scavenger receptor class B type I (SR-BI)] activity of three classes of clinical and experimental plasma HDL-cholesterol-elevating compounds: niacin, fibrates, and HDL376. Fenofibrate (FF) and HDL376 were potent (IC(50) approximately 1 microM), direct inhibitors of SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI. FF, a prodrug, was a more potent inhibitor of SR-BI than an activator of peroxisome proliferator-activated receptor alpha, a target of its active fenofibric acid (FFA) derivative. Nevertheless, FFA, four other fibrates (clofibrate, gemfibrozil, ciprofibrate, and bezafibrate), and niacin had little, if any, effect on SR-BI, suggesting that they do not directly target SR-BI in vivo. However, similarities of HDL376 treatment and SR-BI gene knockout on HDL metabolism in vivo (increased HDL-cholesterol and HDL particle sizes) and structure-activity relationship analysis suggest that SR-BI may be a target of HDL376 in vivo. HDL376 and other inhibitors may help elucidate SR-BI function in diverse mammalian models and determine the therapeutic potential of SR-BI-directed pharmaceuticals. |
| Year of Publication | 2007 |
| Journal | Journal of lipid research |
| Volume | 48 |
| Issue | 8 |
| Pages | 1832-45 |
| Date Published (YYYY/MM/DD) | 2007/08/01 |
| ISSN Number | 0022-2275 |
| DOI | 10.1194/jlr.M700209-JLR200 |
| PubMed | http://www.ncbi.nlm.nih.gov/pubmed/17533223?dopt=Abstract |
Share This
- Tweet
